1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long

Antibody Products Will Be An Important Option Until Vaccines Reduce Infections

 
• By Alaric DeArment

Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.

Coronavirus
Regeneron has received an EUA for its two-antibody cocktail for SARS-CoV-2 infection. • Source: Shutterstock

Regeneron Pharmaceuticals, Inc.’s two-antibody cocktail for coronavirus infection, REGN-COV2 (casirivimab/imdevimab), will join Eli Lilly and Company’s antibody product, helping to ease the immediate demand for a COVID-19 treatment, but the long-term potential of these antibody treatments remains uncertain as the introduction of vaccines are expected to taper off infections.

On 21 November, Regeneron received an emergency use authorization for casirivimab and imdevimab (previously known as REGN-COV2 or REGEN-COV2) from the US Food and Drug Administration, for use in recently diagnosed, mild to moderate COVID-19 among patients aged 12 and older and weighing at least 40 kg who – based on

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.